Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA
Over the course of the day, there are several companies that may come into focus, and one of those could be Tiziana Life Sciences Ltd. (Nasdaq: TLSA), which made a major new announcement on Wednesday. The biotech company, which is involved in developing breakthrough therapies, made an announcement with regards to a regulatory development.
IND Filed with the FDA
In a development that may come as a source of considerable optimism among the company’s shareholders, Tiziana Life Sciences announced that it had filed the IND (investigational new drug) application with the United States Food and Drug Administration for the ALS Phase 2 clinical trial. In the news release, the company stated that the major step signified a pivotal step in advancing its commitment to provide a new approach to the treatment of ALS (amyotrophic lateral sclerosis).
Further Information
Tiziana Life Sciences also announced in the same news release that the IND filing came close on the heels of a prestigious grant award to the company from the ALS Clinical Trial Awards Program of the ALS Association. Thanks to the grant, the company would be able to participate in collaborations with academic institutions.
CEO Quote
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, “We are excited to initiate this important clinical study with the support of the ALS Association grant. This filing represents a significant achievement for our team and underscores our commitment to addressing the urgent medical needs of ALS patients.”
Technicals
| +/- EMA(20) | 0.98 (+38.78%) |
| +/- SMA(50) | 0.8 (+70.00%) |
| +/- SMA(200) | 0.92 (+47.83%) |
| 5-Day Perf. | +38.78% |
| 1-Month Perf. | +106.06% |
| 3-Month Perf. | +33.33% |
| 6-Month Perf. | +58.07% |
| YTD Perf. | +95.35% |
| 1-Year Perf. | +164.08% |
| RSI(14) | 72.93 |
| ATR(14) | 0.14 |
| ADX(14) | 27.38 |
| Beta (5Y) | 0.41 |
